Advertisement
CVM or DYAI or GILD
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CVM’s FA Score shows that 0 FA rating(s) are green whileDYAI’s FA Score has 0 green FA rating(s), and GILD’s FA Score reflects 4 green FA rating(s).
- CVM’s FA Score: 0 green, 5 red.
- DYAI’s FA Score: 0 green, 5 red.
- GILD’s FA Score: 4 green, 1 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CVM’s TA Score shows that 6 TA indicator(s) are bullish while DYAI’s TA Score has 3 bullish TA indicator(s), and GILD’s TA Score reflects 3 bullish TA indicator(s).
- CVM’s TA Score: 6 bullish, 3 bearish.
- DYAI’s TA Score: 3 bullish, 2 bearish.
- GILD’s TA Score: 3 bullish, 3 bearish.
Price Growth
CVM (@Biotechnology) experienced а +19.83% price change this week, while DYAI (@Biotechnology) price change was -1.56% , and GILD (@Pharmaceuticals: Major) price fluctuated -3.40% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +2.37%. For the same industry, the average monthly price growth was +15.66%, and the average quarterly price growth was +33.77%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +0.22%. For the same industry, the average monthly price growth was +3.58%, and the average quarterly price growth was +9.84%.
Reported Earning Dates
CVM is expected to report earnings on May 15, 2025.
DYAI is expected to report earnings on Aug 06, 2025.
GILD is expected to report earnings on Oct 23, 2025.
Industries' Descriptions
@Biotechnology (+2.37% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Pharmaceuticals: Major (+0.22% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| CVM | DYAI | GILD | |
| Capitalization | 22.3M | 30.1M | 90.8B |
| EBITDA | -21.96M | -5.32M | 10.5B |
| Gain YTD | -63.741 | -42.857 | 18.885 |
| P/E Ratio | N/A | N/A | 16.20 |
| Revenue | 0 | 3.34M | 27.1B |
| Total Cash | 1.92M | 7.35M | 7.26B |
| Total Debt | 10.5M | 5.07M | 25B |
CVM | DYAI | GILD | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 1 | 6 | 23 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 98 Overvalued | 94 Overvalued | 18 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | 17 | |
SMR RATING 1..100 | 100 | 99 | 29 | |
PRICE GROWTH RATING 1..100 | 61 | 86 | 22 | |
P/E GROWTH RATING 1..100 | 50 | 70 | 100 | |
SEASONALITY SCORE 1..100 | n/a | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
GILD's Valuation (18) in the Biotechnology industry is significantly better than the same rating for DYAI (94) and is significantly better than the same rating for CVM (98). This means that GILD's stock grew significantly faster than DYAI’s and significantly faster than CVM’s over the last 12 months.
GILD's Profit vs Risk Rating (17) in the Biotechnology industry is significantly better than the same rating for DYAI (100) and is significantly better than the same rating for CVM (100). This means that GILD's stock grew significantly faster than DYAI’s and significantly faster than CVM’s over the last 12 months.
GILD's SMR Rating (29) in the Biotechnology industry is significantly better than the same rating for DYAI (99) and is significantly better than the same rating for CVM (100). This means that GILD's stock grew significantly faster than DYAI’s and significantly faster than CVM’s over the last 12 months.
GILD's Price Growth Rating (22) in the Biotechnology industry is somewhat better than the same rating for CVM (61) and is somewhat better than the same rating for DYAI (86). This means that GILD's stock grew somewhat faster than CVM’s and somewhat faster than DYAI’s over the last 12 months.
CVM's P/E Growth Rating (50) in the Biotechnology industry is in the same range as DYAI (70) and is somewhat better than the same rating for GILD (100). This means that CVM's stock grew similarly to DYAI’s and somewhat faster than GILD’s over the last 12 months.
| CVM | DYAI | GILD | |
|---|---|---|---|
| RSI ODDS (%) | 1 day ago 90% | N/A | N/A |
| Stochastic ODDS (%) | 1 day ago 88% | 1 day ago 85% | 1 day ago 58% |
| Momentum ODDS (%) | 1 day ago 83% | 1 day ago 85% | 1 day ago 49% |
| MACD ODDS (%) | N/A | N/A | 1 day ago 35% |
| TrendWeek ODDS (%) | 1 day ago 83% | 1 day ago 79% | 1 day ago 49% |
| TrendMonth ODDS (%) | 1 day ago 83% | 1 day ago 76% | 1 day ago 60% |
| Advances ODDS (%) | 5 days ago 81% | 12 days ago 80% | 12 days ago 58% |
| Declines ODDS (%) | 15 days ago 90% | 8 days ago 87% | 4 days ago 50% |
| BollingerBands ODDS (%) | 1 day ago 90% | N/A | N/A |
| Aroon ODDS (%) | 1 day ago 78% | 1 day ago 88% | 1 day ago 42% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| NFLY | 18.00 | 0.35 | +1.98% |
| YieldMax NFLX Option Income Strategy ETF | |||
| EMEQ | 31.07 | 0.15 | +0.50% |
| Macquarie Focused Emerging Mrkts Eq ETF | |||
| MGC | 229.07 | 0.70 | +0.31% |
| Vanguard Mega Cap ETF | |||
| IQM | 77.51 | -0.34 | -0.44% |
| Franklin Intelligent Machines ETF | |||
| OSCV | 36.32 | -0.28 | -0.77% |
| Opus Small Cap Value Plus ETF | |||
DYAI and
Correlation & Price change
A.I.dvisor tells us that DYAI and MDGL have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that DYAI and MDGL's prices will move in lockstep.
| Ticker / NAME | Correlation To DYAI | 1D Price Change % | ||
|---|---|---|---|---|
| DYAI | 100% | +2.69% | ||
| MDGL - DYAI | 29% Poorly correlated | -0.95% | ||
| FATE - DYAI | 28% Poorly correlated | +1.77% | ||
| CGTX - DYAI | 28% Poorly correlated | +7.03% | ||
| TAOX - DYAI | 27% Poorly correlated | -8.90% | ||
| QSI - DYAI | 26% Poorly correlated | -2.27% | ||
More | ||||
GILD and
Correlation & Price change
A.I.dvisor indicates that over the last year, GILD has been loosely correlated with AMGN. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if GILD jumps, then AMGN could also see price increases.
| Ticker / NAME | Correlation To GILD | 1D Price Change % | ||
|---|---|---|---|---|
| GILD | 100% | +0.06% | ||
| AMGN - GILD | 49% Loosely correlated | +0.38% | ||
| BMY - GILD | 47% Loosely correlated | -1.41% | ||
| GSK - GILD | 44% Loosely correlated | -0.30% | ||
| ABBV - GILD | 42% Loosely correlated | -2.33% | ||
| PFE - GILD | 42% Loosely correlated | -0.86% | ||
More | ||||